| abstract |
The physiological role of IGFBP-3 in respiratory inflammation and hypersensitivity is currently unknown. The present invention is based on the unexpected finding that both wild type IGFBP-3 and GGG-IGFBP-3 variants, IGGBP-3 variants, inhibit tissue inflammation and hypersensitivity associated with obstructive respiratory diseases such as bronchial asthma. By administering a recombinant IGFBP-3 or IGFBP-3 variant, or a vector encoding an IGFBP-3 or IGFBP-3 variant, methods are provided for treating various diseases associated with airway hypersensitivity including asthma and obstructive respiratory disease. |